• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Lilly touts Ph3 data for once-weekly Type II diabetes medication

February 26, 2018 By Sarah Faulkner

Eli LillyEli Lilly (NYSE:LLY) touted data today from a Phase IIIb study of its once-weekly, injectable Type II diabetes medication, Trulicity.

The insulin-maker reported that its GLP-1 receptor agonist significantly improved blood sugar control in people with Type II diabetes when added to ongoing treatment with a SGLT-2 inhibitor.

“I’ve seen in my practice that even with effective oral medicines like SGLT-2 inhibitors and metformin, many adults with Type II diabetes may still need additional therapy to maintain their blood sugar levels,” lead author Dr. Bernhard Ludvik said in prepared remarks. “The Award-10 results suggest that the combination of once-weekly Trulicity and an SGLT-2 inhibitor shows significant promise in helping more people with type 2 diabetes reach their treatment goals.”

The 424-patient study showed that after 24 weeks, both doses of Trulicity in combination with an SGLT-2 inhibitor demonstrated statistically better blood sugar control compared to an SGLT-2 inhibitor combined with a placebo.

The researchers also found that more people treated with Trulicity reached target A1c levels compared to the placebo group.

Study participants reported treatment-related adverse events like nausea and vomiting – all of which were consistent with previous studies, according to Eli Lilly.

“Managing Type II diabetes with diet, exercise and oral medications may require the addition of injectable therapy for some people, given the progressive nature of the disease,” Dr. Brad Woodward, senior medical director of Lilly Diabetes, added. “Award-10 showed that Trulicity, when used in combination with an SGLT-2 inhibitor and metformin, may be effective and well tolerated in people with type 2 diabetes.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Eli Lilly & Co.

IN CASE YOU MISSED IT

  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS